1712P Efficacy and safety of cabozantinib (CABO) for advanced lung and thymic neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of phase III CABINET Trial (Alliance A021602)
Edward M. Wolin(Icahn School of Medicine at Mount Sinai), T. Zemla(Alliance Data (United States)), Susan M. Geyer(Alliance Data (United States)), Jonathan Strosberg(Moffitt Cancer Center), Þorvarður R. Hálfdánarson(Mayo Clinic in Florida), Nikolaos A. Trikalinos(Washington University in St. Louis), Michael Knopp(University of Cincinnati), Spencer C. Behr(University of California, San Francisco), Sydney Pulsipher(Alliance for Clinical Trials in Oncology), Jared D. Acoba(Cancer Center of Hawaii), Amandeep K. Shergill(University of Chicago), N. Vijayvergia(Fox Chase Cancer Center), Caiyun Liao(University of Chicago), C. Chandrasekharan(University of Iowa Hospitals and Clinics), N.A. Dasari(The University of Texas MD Anderson Cancer Center), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), J. A. Meyerhardt(Dana-Farber Cancer Institute), Jennifer A. Chan(Dana-Farber Cancer Institute)
Cited by 1
Abstract
Related Papers
No related papers found
Powered by citation graph analysis